Prognostic Value of Tumor Necrosis in Gastrointestinal Stromal Tumor: A Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Apr 28

PMID 31027106

Citations 11

Authors

Mengshi Yi

Lin Xia

Yan Zhou

Xiaoting Wu

Wen Zhuang

Yi Chen

Rui Zhao

Qianyi Wan

Liang Du

Yong Zhou

Affiliations

Soon will be listed here.

Abstract

Background And Aims: There is currently no consensus regarding the influence of tumor necrosis on the prognosis of gastrointestinal stromal tumors (GISTs). Therefore, we conducted a meta-analysis to determine the prognostic role of tumor necrosis in patients with GIST.

Methods: PubMed, Embase, and Web of Science electronic databases were searched from their inception to March 2018. Studies reporting data on the relationship between tumor necrosis and GIST prognosis were eligible. The measure of the effect of interest was the odds ratios (ORs) with 95% confidence intervals (CIs). This study has been registered in the Prospero (number CRD42018096036).

Results: In total, 18 studies including 2320 patients were identified. The total odds of tumor necrosis were associated with a poor GIST prognosis (OR = 5.54, 95% CI = 4.39-6.99). Subgroup analysis of different observed outcomes indicated that tumor necrosis was associated with a decreased disease-free survival (OR = 7.08, 95% CI = 4.78-10.49), recurrence-free survival (OR = 3.96, 95% CI = 2.48-6.32), and overall survival (OR = 4.29, 95% CI = 2.02-9.13). In addition, any tumor site, tumor size, follow-up time, ethnicity, different outcomes of GIST, and different degrees of positive staining of immunohistochemical markers subgroups showed a significantly increased risk of a poor prognosis.

Conclusions: Tumor necrosis may likely predict a poorer prognosis for GIST. However, further well-designed prospective studies with large sample size are required in the future.

Citing Articles

Prognostic Nutritional Index is a valuable preoperative prognostic biomarker in Mexican patients surgically intervened on gastrointestinal stromal tumors: a retrospective cohort study.

Herrera-Goepfert R, Soca-Chafre G, Onate-Ocana L, Montiel-Davalos A, Rodriguez-Maldonado E, Castro-Martinez E Support Care Cancer. 2024; 33(1):1.

PMID: 39625513 DOI: 10.1007/s00520-024-09054-5.

Histopathological significance of necrosis in oral lesions: A review.

Fathima S, Gururaj N, Sivapathasundharam B, Vennila A, Keerthik Lavanya M, Sarayushivani U J Oral Maxillofac Pathol. 2023; 27(2):340-347.

PMID: 37854904 PMC: 10581306. DOI: 10.4103/jomfp.jomfp_39_23.

Toxoplasma gondii-derived antigen modifies tumor microenvironment of Ehrlich solid carcinoma murine model and enhances immunotherapeutic activity of cyclophosphamide.

Ismail C, Eissa M, Gaafar M, Younis L, El Skhawy N Med Oncol. 2023; 40(5):136.

PMID: 37014499 PMC: 10073061. DOI: 10.1007/s12032-023-01994-y.

Is tumor necrosis a clinical prognostic factor in hepato-biliary-pancreatic cancers? A systematic review and meta-analysis.

Yang S, Hu H, Hu Y, Dai Y, Zou R, Lv T Cancer Med. 2023; 12(10):11166-11176.

PMID: 36951535 PMC: 10242339. DOI: 10.1002/cam4.5742.

Liver metastases 2 years after resection of a very-low-risk duodenal gastrointestinal stromal tumor: a case report.

Mita J, Tada K, Kuboyama Y, Hiroshige S, Nakamura S, Takahashi J Surg Case Rep. 2022; 8(1):195.

PMID: 36214924 PMC: 9550939. DOI: 10.1186/s40792-022-01551-1.

References

Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T . Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer. 2010; 103(7):1057-65. PMC: 2965866. DOI: 10.1038/sj.bjc.6605854. View

Bucher P, Taylor S, Villiger P, Morel P, Brundler M . Are there any prognostic factors for small intestinal stromal tumors?. Am J Surg. 2004; 187(6):761-6. DOI: 10.1016/j.amjsurg.2003.09.010. View

Vakkila J, Lotze M . Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004; 4(8):641-8. DOI: 10.1038/nri1415. View

Park C, Lee E, Kim M, Lim H, Choi D, Noh J . Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg. 2008; 247(6):1011-8. DOI: 10.1097/SLA.0b013e3181724f9d. View

Vij M, Agrawal V, Kumar A, Pandey R . Evaluation of biologic potential and risk stratification for predicting disease-free survival after resection of primary gastrointestinal stromal tumor: A multivariate clinicopathological study. Indian J Cancer. 2016; 52(3):351-7. DOI: 10.4103/0019-509X.176689. View

Pekarek L, Starr B, Toledano A, Schreiber H . Inhibition of tumor growth by elimination of granulocytes. J Exp Med. 1995; 181(1):435-40. PMC: 2191807. DOI: 10.1084/jem.181.1.435. View

Proskuryakov S, Gabai V . Mechanisms of tumor cell necrosis. Curr Pharm Des. 2010; 16(1):56-68. DOI: 10.2174/138161210789941793. View

Herman J, Baylin S . Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349(21):2042-54. DOI: 10.1056/NEJMra023075. View

DeMatteo R, Ballman K, Antonescu C, Maki R, Pisters P, Demetri G . Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9669):1097-104. PMC: 2915459. DOI: 10.1016/S0140-6736(09)60500-6. View

10.

Wozniak A, Rutkowski P, Schoffski P, Ray-Coquard I, Hostein I, Schildhaus H . Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST. Clin Cancer Res. 2014; 20(23):6105-16. DOI: 10.1158/1078-0432.CCR-14-1677. View

11.

Yan H, Marchettini P, Acherman Y, Gething S, Brun E, Sugarbaker P . Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol. 2003; 26(3):221-8. DOI: 10.1097/01.COC.0000018296.45892.CE. View

12.

Valsangkar N, Sehdev A, Misra S, Zimmers T, ONeil B, Koniaris L . Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy. Surgery. 2015; 158(5):1149-64. DOI: 10.1016/j.surg.2015.06.027. View

13.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279(5350):577-80. DOI: 10.1126/science.279.5350.577. View

14.

Yoo C, Koh Y, Park Y, Ryu M, Ryoo B, Park H . Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib. Ann Surg Oncol. 2015; 22 Suppl 3:S362-9. DOI: 10.1245/s10434-015-4506-3. View

15.

Richards C, Roxburgh C, Anderson J, McKee R, Foulis A, Horgan P . Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. Br J Surg. 2011; 99(2):287-94. DOI: 10.1002/bjs.7755. View

16.

Sabo E, Boltenko A, Sova Y, Stein A, Kleinhaus S, Resnick M . Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin Cancer Res. 2001; 7(3):533-7. View

17.

Sengupta S, Lohse C, Leibovich B, Frank I, Thompson R, Webster W . Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005; 104(3):511-20. DOI: 10.1002/cncr.21206. View

18.

Bristow R, Hill R . Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008; 8(3):180-92. DOI: 10.1038/nrc2344. View

19.

Kovecsi A, Jung I, Szentirmay Z, Bara T, Bara Jr T, Popa D . PKCθ utility in diagnosing c-KIT/DOG-1 double negative gastrointestinal stromal tumors. Oncotarget. 2017; 8(34):55950-55957. PMC: 5593536. DOI: 10.18632/oncotarget.19116. View

20.

Emile J, Brahimi S, Coindre J, Bringuier P, Monges G, Samb P . Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2011; 29(3):1765-72. DOI: 10.1007/s12032-011-0074-y. View